Back to resultsEvaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
Primary Purpose
Hypersomnia, Narcolepsy, Traumatic Brain Injury
Status
Withdrawn
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
Sodium Oxybate Oral Solution [Xyrem]
Sponsored by
About this trial
This is an interventional treatment trial for Hypersomnia focused on measuring Excessive Daytime Sleepiness, Prolonged sleep, Traumatic Brain Injury
Eligibility Criteria
Inclusion Criteria:
- History of first-ever primary TBI 12 or more months ago;
- Mild to severe TBI (GCS 3-15);
Either a) or b):
- Presence of subjective daytime sleepiness (ESS ≥ 10) lasting 3 months or more, and not present prior to the TBI;
- Long sleep duration (mean TST ≥ 9hours/24hrs or increased sleep need of at least 1-2 h per 24 h compared to pre-TBI), documented by actigraphy, lasting 3 months or more;
- Objectively demonstrated EDS (MSLT mean of 5 naps: SL ≤ 8min);
- Age: 18 - 64;
- Ability to read and understand consent form, complete questionnaires and daily sleep diary, and provide informed consent. The Folstein MMSE will be used to assess cognitive function.
Exclusion Criteria:
- Current neurologic deficit (weakness, dysarthria or dysphagia, aphasia or dysphasia); Participants with a score of <27 on Folstein MMSE will be excluded.
- History of neurologic or psychiatric disease prior to TBI;
- Epilepsy or history of seizure (whether related or unrelated to TBI);
- Body mass index (BMI) ≥ 32;
- Sleep apnea (Apnea Hypopnea Index, AHI > 15/h); -Chronic sleep restriction (≥ 2hour sleep extension on weekends from self- report, diary, or at least 14 days of actigraphy);
- Sleep-wake disturbance other than long sleep duration or sleepiness (DSPD, ASPD, Shift-work Sleep Disorder);
- Diagnosis of narcolepsy or other sleep disorder prior to TBI;
- Unwillingness to follow physician instructions relating to the concomitant use of alcohol and sodium oxybate during the study;
- History of or current substance abuse;
- Current regular CNS-affecting medication use;
- History of depression, suicidal thoughts, and/or post-traumatic stress disorder (PTSD);
- Current depression assessed by a structured clinical interview and Beck Depression Inventory (BDI);
- Abnormal liver function (LFT more than twice the upper limit of normal or serum bilirubin more than 1.5 times the upper limit of normal);
- Hypertension, heart failure, history of myocardial infarction, or abnormal EKG demonstrating clinically significant arrhythmia;
- Kidney disease (Serum creatinine >2.0mg/dl);
- Lung disease (COPD, ILD, asthma);
- On a low salt diet for medical reasons;
- An occupation that requires variable shift work or routine night shifts (work hours between 11pm and 6am);
- Pregnant, intention to become pregnant;
- Breast-feeding or plans to breastfeed;
- Succinic semialdehyde dehydrogenase deficiency.
Sites / Locations
- Brigham and Women's Hospital
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Sodium Oxybate Oral Solution (Xyrem®)
Arm Description
4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
Outcomes
Primary Outcome Measures
Change in Subjective Daytime Sleepiness
Change in subjective daytime sleepiness assessed through a daily questionnaire about frequency and duration of daytime naps, frequency of sleep attacks.
Change in Sleep Duration
Change in sleep duration assessed by actigraphy-estimated total sleep time (TST).
Change in Clinical Condition
Change in clinical condition as assessed by Clinical Global Impression (CGI) assessment. CGI assesses a clinician's view of a patient's global functioning before and after initiating medication. It is broken up into CGI-S (Severity) and CGI-I (Improvement). CGI-S is one question assesses how clinically ill a patient is at time of assessment. it is on a 1-7 scale with 1 being normal and 7 being among the most extremely ill patients. CGI-I looks at improvement in patients functioning once medication starts. it is also on a 1-7 scale with 1 being very much improved since initiation of treatment and 7 being very much worse.
Change in Subjective Daytime Sleepiness (ESS)
Change in daytime sleepiness will be assessed through changes in Epworth Sleepiness Scale (ESS) scores. The ESS measures sleepiness of a participant. It is eight questions with a scale of 0 - 3 with 0 being no chance of dozing and 3 being high chance of dozing. The total score of eight questions is reported.
Secondary Outcome Measures
Change in Nocturnal Sleep Quality (Frequency of nocturnal awakenings)
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on frequency of nocturnal awakenings.
Change in Nocturnal Sleep Quality (Duration of nocturnal awakenings)
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on duration of nocturnal awakenings.
Change in Nocturnal Sleep Quality (Subjective amount of sleep)
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on subjective amount of sleep each night.
Change in Nocturnal Sleep Quality (Frequency of sleep walking)
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on frequency of sleep walking.
Change in Nocturnal Sleep Quality (Frequency of hypnagogic hallucinations)
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on frequency of hypnagogic hallucinations.
Change in Nocturnal Sleep Quality (Change in Pittsburgh Sleep Quality index) scores)
Average change in nocturnal sleep quality assessed by changes in Pittsburgh Sleep Quality Index (PSQI) scores. The PSQI assesses sleep quality. It is broken down into seven components, with scales from 0 - 3 with 0 being better quality of sleep and 3 being a more poor quality of sleep. The Global PSQI score is taken from the sum of the seven component scores.
Change in Nocturnal Sleep Quality (actigraphy)
Average change in nocturnal sleep quality measured by actigraphy.
Change in Global Functioning
Change in global functioning evaluated by the Sheehan Disability Scale (SDS). The SDS assesses functional impairment in three subscales: in work/school, social, and family life. Each is subscale is 1-10 with 1 being no disability/impairment and 10 be extreme disability/impairment. These three subscales are added together to give the global functional impairment score which ranges from 0 being unimpaired to 30 being highly impaired.
Full Information
NCT ID
NCT03626727
First Posted
June 27, 2018
Last Updated
March 2, 2021
Sponsor
Brigham and Women's Hospital
1. Study Identification
Unique Protocol Identification Number
NCT03626727
Brief Title
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
Official Title
Open-label Clinical Trial to Evaluate the Efficacy of Sodium Oxybate (Xyrem®) in the Treatment of Two Under-recognized Clinical Conditions: Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
Study Type
Interventional
2. Study Status
Record Verification Date
March 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Target study population was extremely difficult to recruit and planned study budget was exceeded
Study Start Date
September 2020 (Anticipated)
Primary Completion Date
September 1, 2020 (Actual)
Study Completion Date
September 1, 2020 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Brigham and Women's Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
The study evaluates whether the use of Sodium Oxybate (Xyrem®) in TBI patients will be effective in reducing symptoms of post traumatic narcolepsy and post traumatic hypersomnia.
Detailed Description
Post-traumatic narcolepsy and post-traumatic hypersomnia are under-recognized clinical conditions in post-TBI patients.
Considering the high prevalence of hypersomnia, treatment difficulty, and sparse clinical studies for treatment of sleep problems in TBI patients, additional clinical trials need to be performed to provide more therapeutic options for patients and physicians. Sodium oxybate (Xyrem®) could be potentially one such option given its high efficacy in idiopathic narcolepsy patients.
From the results of animal research, as well as from cerebrospinal fluid (CSF) and autopsy findings from TBI patients, hypothalamic injury and hypocretin pathology seem to play a role in the pathogenesis of post-traumatic narcolepsy and hypersomnia. Despite lack of clear understanding of the exact mechanism of action of sodium oxybate in patients with idiopathic narcolepsy, the shared pathophysiology of the hypocretin system in post-traumatic hypersomnia and narcolepsy would suggest the possible efficacy of sodium oxybate (Xyrem®) on excessive daytime sleepiness (EDS) and prolonged sleep in patients with TBI.
In this Pilot Clinical Trial, we will test whether sodium oxybate (Xyrem®, approved for the treatment of improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy) is effective in improving the sleep-wake symptoms, global functioning and quality of life of post-TBI patients with hypersomnia and narcolepsy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypersomnia, Narcolepsy, Traumatic Brain Injury
Keywords
Excessive Daytime Sleepiness, Prolonged sleep, Traumatic Brain Injury
7. Study Design
Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Sodium Oxybate Oral Solution (Xyrem®)
Arm Type
Experimental
Arm Description
4.5g of oral solution Xyrem will be given as a starting dose. This will be titrated up weekly to the final treatment dose of 9.0g. Participants will be on this final dose for 8 weeks.
Intervention Type
Drug
Intervention Name(s)
Sodium Oxybate Oral Solution [Xyrem]
Intervention Description
Xyrem will be given to participants to determine if it is effective in treating post-traumatic narcolepsy and post-traumatic hypersomnia
Primary Outcome Measure Information:
Title
Change in Subjective Daytime Sleepiness
Description
Change in subjective daytime sleepiness assessed through a daily questionnaire about frequency and duration of daytime naps, frequency of sleep attacks.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Sleep Duration
Description
Change in sleep duration assessed by actigraphy-estimated total sleep time (TST).
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Clinical Condition
Description
Change in clinical condition as assessed by Clinical Global Impression (CGI) assessment. CGI assesses a clinician's view of a patient's global functioning before and after initiating medication. It is broken up into CGI-S (Severity) and CGI-I (Improvement). CGI-S is one question assesses how clinically ill a patient is at time of assessment. it is on a 1-7 scale with 1 being normal and 7 being among the most extremely ill patients. CGI-I looks at improvement in patients functioning once medication starts. it is also on a 1-7 scale with 1 being very much improved since initiation of treatment and 7 being very much worse.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Subjective Daytime Sleepiness (ESS)
Description
Change in daytime sleepiness will be assessed through changes in Epworth Sleepiness Scale (ESS) scores. The ESS measures sleepiness of a participant. It is eight questions with a scale of 0 - 3 with 0 being no chance of dozing and 3 being high chance of dozing. The total score of eight questions is reported.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Secondary Outcome Measure Information:
Title
Change in Nocturnal Sleep Quality (Frequency of nocturnal awakenings)
Description
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on frequency of nocturnal awakenings.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Nocturnal Sleep Quality (Duration of nocturnal awakenings)
Description
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on duration of nocturnal awakenings.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Nocturnal Sleep Quality (Subjective amount of sleep)
Description
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on subjective amount of sleep each night.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Nocturnal Sleep Quality (Frequency of sleep walking)
Description
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on frequency of sleep walking.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Nocturnal Sleep Quality (Frequency of hypnagogic hallucinations)
Description
Average change in nocturnal sleep quality assessed by a daily sleep questionnaire on frequency of hypnagogic hallucinations.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Nocturnal Sleep Quality (Change in Pittsburgh Sleep Quality index) scores)
Description
Average change in nocturnal sleep quality assessed by changes in Pittsburgh Sleep Quality Index (PSQI) scores. The PSQI assesses sleep quality. It is broken down into seven components, with scales from 0 - 3 with 0 being better quality of sleep and 3 being a more poor quality of sleep. The Global PSQI score is taken from the sum of the seven component scores.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Nocturnal Sleep Quality (actigraphy)
Description
Average change in nocturnal sleep quality measured by actigraphy.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
Title
Change in Global Functioning
Description
Change in global functioning evaluated by the Sheehan Disability Scale (SDS). The SDS assesses functional impairment in three subscales: in work/school, social, and family life. Each is subscale is 1-10 with 1 being no disability/impairment and 10 be extreme disability/impairment. These three subscales are added together to give the global functional impairment score which ranges from 0 being unimpaired to 30 being highly impaired.
Time Frame
Data collected on Day 1 (Baseline Visit) of the Intervention and at end of 1 week on the final dosage, which will be 2-5 weeks after the Baseline Visit.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
64 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
History of first-ever primary TBI 12 or more months ago;
Mild to severe TBI (GCS 3-15);
Either a) or b):
Presence of subjective daytime sleepiness (ESS ≥ 10) lasting 3 months or more, and not present prior to the TBI;
Long sleep duration (mean TST ≥ 9hours/24hrs or increased sleep need of at least 1-2 h per 24 h compared to pre-TBI), documented by actigraphy, lasting 3 months or more;
Objectively demonstrated EDS (MSLT mean of 5 naps: SL ≤ 8min);
Age: 18 - 64;
Ability to read and understand consent form, complete questionnaires and daily sleep diary, and provide informed consent. The Folstein MMSE will be used to assess cognitive function.
Exclusion Criteria:
Current neurologic deficit (weakness, dysarthria or dysphagia, aphasia or dysphasia); Participants with a score of <27 on Folstein MMSE will be excluded.
History of neurologic or psychiatric disease prior to TBI;
Epilepsy or history of seizure (whether related or unrelated to TBI);
Body mass index (BMI) ≥ 32;
Sleep apnea (Apnea Hypopnea Index, AHI > 15/h); -Chronic sleep restriction (≥ 2hour sleep extension on weekends from self- report, diary, or at least 14 days of actigraphy);
Sleep-wake disturbance other than long sleep duration or sleepiness (DSPD, ASPD, Shift-work Sleep Disorder);
Diagnosis of narcolepsy or other sleep disorder prior to TBI;
Unwillingness to follow physician instructions relating to the concomitant use of alcohol and sodium oxybate during the study;
History of or current substance abuse;
Current regular CNS-affecting medication use;
History of depression, suicidal thoughts, and/or post-traumatic stress disorder (PTSD);
Current depression assessed by a structured clinical interview and Beck Depression Inventory (BDI);
Abnormal liver function (LFT more than twice the upper limit of normal or serum bilirubin more than 1.5 times the upper limit of normal);
Hypertension, heart failure, history of myocardial infarction, or abnormal EKG demonstrating clinically significant arrhythmia;
Kidney disease (Serum creatinine >2.0mg/dl);
Lung disease (COPD, ILD, asthma);
On a low salt diet for medical reasons;
An occupation that requires variable shift work or routine night shifts (work hours between 11pm and 6am);
Pregnant, intention to become pregnant;
Breast-feeding or plans to breastfeed;
Succinic semialdehyde dehydrogenase deficiency.
Facility Information:
Facility Name
Brigham and Women's Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02115
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
We'll reach out to this number within 24 hrs